ClinicalTrials.gg
RecruitingNCT06956690Updated Mar 2, 2026

A Phase 1/2 Clinical Trial to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMBD-501 in Patients With HER3-Expressing Solid Tumors

A Phase 1/2 interventional study of ENV-501 in Melanoma (Skin), Non Small Cell Lung Cancer and Breast Cancer, sponsored by Hummingbird Bioscience. Recruiting at 7 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-02.

Sponsored by Hummingbird Bioscience · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Started Dec 2025; still recruiting 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
180
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 2,050 studies in Melanoma with a site in United States — 244 open to participants now, 438 under way, 32 of them phase 3. Melanoma · United States.

Planned enrollment
253rd of 1,750
180 · median 37
Started
2025
with 61 others
Phase 1/2
287 of 2,050
51 open now
Primary completion
2027-07
later than 217 of 433 live
Registered
1,967th of 2,050
by date

Among the 2,050 studies in Melanoma with a site in United States, this one is the 253rd largest by planned enrollment of the 1,750 interventional ones that give a count, is one of 62 that started in 2025, is one of 287 in phase 1/2, reaches primary completion later than 217 of the 433 other live ones, and was the 1,967th registered.

Melanoma

3,373 studies on the registry are indexed under Melanoma; 580 are open to participants now.

Browse Melanoma studies →

Open to participants now

244 of the 2,050 studies in Melanoma with a site in United States are open now. Recruiting first, the newest first:

239 more — sign in →

All 244 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 467 Melanoma studies recruiting now, 380 (81%) set no upper age limit and 49 (10%) stop at 75 or younger; 47 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 2,050 studies in Melanoma with a site in United States, or all of them as a file.
02

Study summary

This study is a Phase 1/2, first-in-human, open-label, clinical trial to assess the safety, tolerability, pharmacokinetics and preliminary efficacy of HMBD-501 in patients with advanced-stage, relapsed and/or refractory human epidermal growth factor receptor 3 (HER3)-expressing solid tumors. The study consists of 2 phases: a dose escalation phase (Phase 1) and a dose expansion phase (Phase 2).

The primary objectives of Phase 1 are to characterize the overall safety and tolerability profile of increasing doses of HMBD-501 in patients with advanced-stage solid tumors and identify the recommended Phase 2 dose (RP2D) of ENV-501. During Phase 1, successive cohorts of patients will receive escalating doses of HMBD-501. The results of the dose escalation will determine the RP2D and dosing schedule of HMBD-501 to be administered in the Phase 2 part of the study. The primary objective of Phase 2 is to evaluate the preliminary clinical efficacy of HMBD-501 in dose expansion cohorts.

03

Conditions studied

  • Melanoma (Skin)
  • Non Small Cell Lung Cancer
  • Breast Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Body weight ≥ 40 kg.
  • Willing and able to provide signed written before any study-related screening procedures are performed.
  • Patients with or cytologically confirmed diagnosis of advanced-stage or HER3+ solid tumors that are to or ineligible for standard therapy, or for whom no standard therapy is available; or the patient has documented their refusal of standard of care therapies. These include the following:

    1. Unresectable or metastatic cutaneous melanoma (HER3+)
    2. Locally advanced or metastatic mutated EGFR (mEGFR) NSCLC (HER3+)
    3. Unresectable, locally advanced or metastatic breast cancer
    4. Relapsed or refractory solid tumors, with documented HER3+ expression such as Pancreatic Ductal Adenocarcinoma (PDAC) and gastric cancers, may be allowed in the protocol following sponsor approval on a case-by -case basis.
  • If molecular pathology report to confirm HER3+ status is not available, willingness to undergo fresh tumor for retrospective assessment of HER3+ status following enrollment..
  • (ECOG) performance status (PS) 0-2.
  • requirements:

    1. Women of (WOCBP) must use contraception from at least 28 days prior to study start, during the study, and for at least 6 months after the last dose of study drug.
    2. Males who are sexually active with partner(s) who are WOCBP must agree to use a male condom with spermicide beginning at study start, during the study and for at least 6 months after the last dose of study drug.
  • Females must:

    1. Agree to not donate eggs (ova, oocytes) for the purposes of assisted reproduction during the study and for at least 6 months after the last dose of study drug.
    2. Agree to not breastfeed and do not plan to become pregnant during the study and for at least 6 months after the last dose of study drug.
  • Males must:

    1. Agree to not donate sperm beginning at study start, during the study, and for at least 6 months after the last dose of study drug.
    2. Agree to not plan to father a child beginning at study start, during the study, and for at least 6 months after last dose of study drug.
  • Willingness and ability to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.

Exclusion criteria

Exclusion Criteria:

  • Any of the following treatment interventions within the specified time frame prior to study drug administration at study start:

    1. Any anti-tumor-directed drug therapy within 21 days or 5 times the elimination half-life (whichever is shorter).
    2. Treatment with drugs within 21 days.
    3. Major surgery within 21 days.
    4. Radiation therapy ≤4 weeks or radiotherapy that included >30% of the bone marrow.
    5. or allogeneic stem cell transplantation or allogeneic tissue/organ transplant within 3 months.
    6. strong inhibitor (including any prescription or non-prescription drugs or herbal supplements) ≤4 half-lives.
    7. CYP3A4 strong inducer ≤4 half-lives.
    8. OATP1B inhibitor (including any prescription or non-prescription drugs or herbal supplements) ≤4 half-lives.
  • Prior treatment with a HER3-targeted ADC or any exatecan- or exatecan-derivative-conjugated ADC inhibitor as last .
  • Prior treatment with a topoisomerase I inhibitor as last line of therapy.
  • Primary immune deficiency (e.g. congenital syndromes).
  • Active and uncontrolled infections requiring intravenous antibiotic or antiviral treatment within 2 weeks prior to study start.
  • Known/suspected against ENV-501, human or humanized immunoglobulin Gs (IgGs), or their ingredients.
  • History of noninfectious or drug-induced pneumonitis or interstitial lung disease (ILD).
  • Known seropositivity (except after vaccination or confirmed cure for hepatitis) for (HIV), virus (HBV), or virus (HCV).
  • , symptomatic or uncontrolled (active) (note: brain metastases not requiring or anti-epileptic therapy are allowed if stable for ≥4 weeks prior to study start and patient is neurologically stable).
  • Pregnant or who have a positive b-human chorionic gonadotropin (HCG) test result at Screening or within 7 days prior to study start.
  • Patients with second that are active (uncontrolled, ) or requiring therapy.
  • Patient who is an immediate family member (spouse, parent, child, or sibling; biological or legally adopted) of personnel directly affiliated with the study site or the Sponsor.
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
180 participants (estimated)

Study arms

  • Experimental
    HMBD-501

    HMBD-501 intravenous injection once every 3 weeks; successive cohorts will receive escalating doses of HMBD-501 until the RP2D is reached

    Biological: ENV-501

Interventions

  • BiologicalENV-501

    ENV-501 is a HER3-targeted antibody-drug conjugate (ADC) with a humanized monoclonal antibody (mAb) conjugated with a chemotherapeutic payload via a linker.

06

What researchers measure

Primary outcomes

  1. Phase 1 (Dose Escalation): Frequency of treatment-emergent adverse events

    Time frame: through study completion, an average of 6 months

  2. Phase 2 (Dose Expansion): Objective Response Rate (ORR)

    Objective Response is defined as Complete Response (CR) or Partial Response (PR) by investigator assessment, measured by revised Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST 1.1).

    Time frame: through study completion, an average of 6 months

Secondary outcomes

  1. Phase 1 (Dose Escalation): Disease Control Rate (DCR)

    DCR is defined as CR, PR, or Stable Disease (SD) by investigator assessment, measured by revised RECIST 1.1.

    Time frame: through study completion, an average of 6 months

  2. Phase 1 (Dose Escalation): Objective Response Rate (ORR)

    Time frame: through study completion, an average of 6 months

  3. Phase 1 (Dose Escalation): maximum blood concentration (Cmax) after a single dose

    Time frame: At the end of Cycle 1 (each cycle is 21 days)

  4. Phase 1 (Dose Escalation): time of maximum blood concentration (Tmax) after a single dose

    Time frame: At the end of Cycle 1 (each cycle is 21 days)

  5. Phase 1 (Dose Escalation): absorption to time t (AUC0-t) after a single dose

    AUC represents "area under the concentration-time curve" and measures the amount of drug that is present in the blood from the time of administration to a given time 't'

    Time frame: At the end of Cycle 1 (each cycle is 21 days)

  6. Phase 1 (Dose Escalation): absorption to end of the dosing period (AUC0-tau) after a single dose

    Time frame: At the end of Cycle 1 (each cycle is 21 days)

  7. Phase 1 (Dose Escalation): total absorption (AUC0-infinity) after a single dose

    Time frame: At the end of Cycle 1 (each cycle is 21 days)

  8. Phase 1 (Dose Escalation): drug half-life (t1/2) after a single dose

    Time frame: At the end of Cycle 1 (each cycle is 21 days)

  9. Phase 1 (Dose Escalation): minimum blood concentration (Cmin) after a single dose

    Time frame: At the end of Cycle 1 (each cycle is 21 days)

  10. Phase 1 (Dose Escalation): rate of clearance (CL) after a single dose

    Time frame: At the end of Cycle 1 (each cycle is 21 days)

  11. Phase 1 (Dose Escalation): steady-state volume of distribution (Vss) after a single dose

    Time frame: At the end of Cycle 1 (each cycle is 21 days)

  12. Phase 1 (Dose Escalation): Cmax at steady state

    Time frame: through study completion, an average of 6 months

  13. Phase 1 (Dose Escalation): Tmax at steady state

    Time frame: through study completion, an average of 6 months

  14. Phase 1 (Dose Escalation): AUC0-t at steady state

    Time frame: through study completion, an average of 6 months

  15. Phase 1 (Dose Escalation):AUC0-tau at steady state

    Time frame: through study completion, an average of 6 months

  16. Phase 1 (Dose Escalation): t1/2 at steady state

    Time frame: through study completion, an average of 6 months

  17. Phase 1 (Dose Escalation): Cmin at steady state

    Time frame: through study completion, an average of 6 months

  18. Phase 1 (Dose Escalation): accumulation ratio at steady state

    Time frame: through study completion, an average of 6 months

  19. Phase 2 (Dose Expansion): Disease Control Rate (DCR)

    Time frame: through study completion, an average of 6 months

  20. Phase 2 (Dose Expansion): Duration of Response (DoR)

    A DoR event is defined as disease progression or death due to any cause in the subset of patients who achieved CR or PR on the study. DoR will be calculated from the date of first radiographic evidence of objective response by RECIST v1.1 to the date of progression, date of death, or date of last follow-up, whichever is the earliest.

    Time frame: through study completion, an average of 6 months

  21. Phase 2 (Dose Expansion): Progression-free Survival (PFS)

    A PFS event is defined as disease progression or death due to any cause. PFS will be calculated from the date of treatment start to the date of progression, date of death, or date of last follow-up, whichever is the earliest.

    Time frame: through study completion, an average of 6 months

  22. Phase 2 (Dose Expansion): Frequency of treatment-emergent adverse events

    Time frame: through study completion, an average of 6 months

  23. Phase 2 (Dose Expansion): Cmax at steady state

    Time frame: through study completion, an average of 6 months

  24. Phase 2 (Dose Expansion): Cmin at steady state

    Time frame: through study completion, an average of 6 months

07

Study locations

5 of 7 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2025 (actual). Primary completion is estimated for Jul 2027, 19 months after the start.

Of 135 industry-sponsored phase 1/2 interventional studies under Melanoma, half reached primary completion within 61 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 84. This study's planned 19 months is below that.

Counting every sponsor, half of 220 studies reached it within 61 months; a quarter within 42 and three quarters within 85.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 24, 2025
First posted
May 4, 2025
StartActual
Dec 17, 2025
Primary completionEst.
Jul 2027
CompletionEst.
Jul 2027
Last update
Mar 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06956690
Lead sponsor
Hummingbird Bioscience
Responsible party
Sponsor
First posted
May 4, 2025
Start date
Dec 17, 2025
Primary completion
Jul 2027 (estimated)
Completion
Jul 2027 (estimated)
Last update
Mar 2, 2026

Study contacts

Kevin Heller, Dr
Contact
HMBD Patients <patients@hummingbirdbio.com>
+65 6978 9377
Hummingbird Bioscience Team
Contact
HMBD Patients <patients@hummingbirdbio.com>
Kevin Heller
study director · Hummingbird Bioscience

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion